Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Catalonia, Spain.
Trends Cancer. 2024 Nov;10(11):1052-1071. doi: 10.1016/j.trecan.2024.08.004. Epub 2024 Sep 6.
Cancer stem cells (CSCs) are a poorly differentiated population of malignant cells that (at least in some neoplasms) is responsible for tumor progression, resistance to therapy, and disease relapse. According to a widely accepted model, all stages of cancer progression involve the ability of neoplastic cells to evade recognition or elimination by the host immune system. In line with this notion, CSCs are not only able to cope with environmental and therapy-elicited stress better than their more differentiated counterparts but also appear to better evade tumor-targeting immune responses. We summarize epigenetic modifications of DNA and histones through which CSCs evade immune recognition or elimination, and propose that such alterations constitute promising therapeutic targets to increase the sensitivity of some malignancies to immunotherapy.
癌症干细胞(CSCs)是一种分化不良的恶性细胞群体,(至少在某些肿瘤中)负责肿瘤的进展、对治疗的耐药性和疾病的复发。根据一个广泛接受的模型,癌症进展的所有阶段都涉及到肿瘤细胞逃避宿主免疫系统识别或消除的能力。与此观点一致,CSCs 不仅能够比其更分化的对应物更好地应对环境和治疗引起的应激,而且似乎更好地逃避针对肿瘤的免疫反应。我们总结了 CSCs 通过逃避免疫识别或消除的 DNA 和组蛋白的表观遗传修饰,并提出这些改变构成了增加某些恶性肿瘤对免疫治疗敏感性的有前途的治疗靶点。